Sarepta slides as surprise FDA panel meet adds uncertainty for gene therapy
...(Reuters) -Shares of Sarepta Therapeutics Inc slumped as much as 21......…
114,450€
-0,13%
Echtzeit-Aktienkurs Sarepta Therapeutics Inc.
Bid:
Ask:
Nachrichten zur Sarepta Therapeutics Inc. Aktie
Sarepta Therapeutics Plunges on Drug Approval Doubts. Buy the Stock, Analysts Say.
THe FDA said it is seeking input from a panel of independent experts on whether to approve a gene therapy…
Pre-market Movers: Enzo Biochem, HUB Cyber Security, Sarepta Therapeutics, Monopar Therapeutics, ThermoGenesis
MEMPHIS (dpa-AFX) - The following are some of the stocks making big moves in Fridays pre-market trading (as of 07.00…
Why Sarepta Therapeutics Shares Are Trading Lower By Around 19%; Here Are 20 Stocks Moving Premarket
Gainers
Enzo Biochem, Inc. (NYSE: ENZ) shares rose 89.9% to $2.26 in pre-market trading after the company announced it will sell…
Sarepta Therapeutics Shares Slide 19% on Unexpected FDA Meeting for SRP-9001
Sarepta Therapeutics Shares Slide 19% on Unexpected FDA Meeting for SRP-9001...…
Sarepta Therapeutics plummets 20% after FDA contradicts company and requires advisory meeting
Sarepta Therapeutics Inc. SRPT shares plummeted in the extended session Thursday after the Food and Drug Administration contradicted the biotech…
Sarepta stock -20% on FDA advisory meeting for its muscular dystrophy treatment
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
2 Biotech Stocks You Can Buy and Hold for the Next Decade
Regeneron and Sarepta Therapeutics have been on fire so far this year....…
Sarepta falls after announcing share exchange agreement
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 8-K Sarepta Therapeutics, For: Mar 02
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Sarepta’s stock still up after Tuesday’s announcement that its Duchenne drug candidate won’t require a FDA AdCom meeting
Shares of Sarepta Therapeutics Inc. SRPT were up 18.7% in trading on Wednesday afternoon, a day after the company told…
Why Sarepta Therapeutics Stock Is Booming Today
Sarepta Therapeutics (NASDAQ: SRPT) shares are trading higher this Wednesday after the company reported better-than-expected fourth-quarter results.
read more...…
Biotech Report: Sektor leichter - MorphoSys (MOR) behauptet, Evotec (EVT) deutlich leichter
Biotech-Aktien zeigten sich im deutschen Handel auf breiter Front schwächer. Evotec und Biontech gaben deutlich nach. MorphoSys ging …
Sarepta (SRPT) Q4 Earnings & Sales Beat Estimates, Stock Up
Sarepta (SRPT) delivers decent fourth-quarter 2022 results. Management confirms that the FDA does not plan to hold an advisory committee…
Why This Sarepta Therapeutics Is Turning Bullish
Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) jumped in early trading on Wednesday, after the company reported an earnings beat…
Sarepta Therapeutics stock price target raised to $180 from $150 at Oppenheimer
Um den gesamten Artikel unter marketwatch.com zu lesen, klicken Sie bitte auf die Überschrift...…
Sarepta Therapeutics (SRPT) Q4 2022 Earnings Call Transcript
SRPT earnings call for the period ending December 31, 2022....…
Sarepta Therapeutics (SRPT) Reports Q4 Loss, Tops Revenue Estimates
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 3.12% and 3.63%, respectively, for the quarter ended December 2022. Do…
Sarepta up 16% after no FDA advisory meeting for Duchenne therapy
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Sarepta stock surges more than 10% as results top expectations, drug given priority review
Sarepta Therapeutics Inc. SRPT shares rallied in the extended session Tuesday after the biotech drug maker topped Wall Street expectations,…
Sarepta Therapeutics Q4 Loss Decreases, beats estimates
WASHINGTON (dpa-AFX) - Sarepta Therapeutics (SRPT) reported Loss for fourth quarter that decreased from the same period last year and…
Hansa Biopharma Year-end report January-December 2022
· Total 2022 revenue of SEK 155m
· Cash runway extended into 2025
· Market Access obtained in…
Hansa Biopharma Year-end report January-December 2022
Total 2022 revenue of SEK 155m Cash runway extended into 2025 Market Access obtained in four of the five largest…
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine…
Sarepta Therapeutics expects 32% net product revenue growth in Q4
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 8-K Sarepta Therapeutics, For: Jan 09
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2022 Net Product Revenues
- The Company expects to exceed 2022 full-year guidance for net product revenues...…
Sarepta Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine…